Savient announces results from KRYSTEXXA Phase III trials on gout …

Post-hoc analysis evaluated more than 200 patients with CKD stages one through four (n=34, 74, 80, 23, respectively) who were randomized to receive treatment with KRYSTEXXA (pegloticase, see structure) 8 mg every other … In another study presented as a poster at EULAR, 35 percent of patients diagnosed with gout in Western Europe reported experiencing pain in the last 30 days (versus 20 percent in the control group of those who did not report gout ; p<0.05).

More: 
Savient announces results from KRYSTEXXA Phase III trials on gout …

No comments yet.

TOP